Contemplating HPV vaccination in Japan during the time of COVID-19

Area of Science:

• Oncology
• Public Health
• Vaccinology

Background:

• The Coronavirus Disease 2019 (COVID-19) pandemic is a growing global health concern.
• Human papillomavirus (HPV) infection is prevalent in Japan, leading to significant cancer risks.
• Japan has a notably low cervical cancer screening rate among developed nations.

Purpose of the Study:

• To highlight the comparable fatality rates of HPV-associated cancers and COVID-19.
• To address the low HPV vaccination rates in Japan following MHLW's recommendation suspension.
• To advocate for increased HPV vaccination acceptance among women.

Main Methods:

• Comparative analysis of fatality rates for COVID-19 and HPV-associated cancers.
• Review of HPV vaccination trends in Japan post-2013.
• Examination of public health messaging regarding vaccination.

Main Results:

• The fatality rate for HPV-associated cancers in Japan is comparable to that of COVID-19.
• HPV vaccination rates in Japan have drastically declined from 70% to below 1% since 2013.
• Media reports on alleged adverse events influenced public perception and policy.

Conclusions:

• HPV vaccination is essential for preventing cervical cancer, a serious health threat in Japan.
• Public health initiatives should encourage HPV vaccination with the same urgency as COVID-19 testing.
• Addressing concerns and restoring confidence in HPV vaccination is critical for improving women's health outcomes.